FDA Frowns on Evolus’ Botox Rival

Wednesday, May 16, 2018 | Fillers & Injectables , Product Launches and Updates


The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues.

As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more here.

Next Story

Comments

You must be logged in to leave a comment.